• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1990 Fiscal Year Final Research Report Summary

Clinical Application of Anti-tumor Cells Which were Induced From Thoracic Duct Lymphocytes With Enriched Contents of Helper and/or Inducer Cells

Research Project

Project/Area Number 63440049
Research Category

Grant-in-Aid for General Scientific Research (A)

Allocation TypeSingle-year Grants
Research Field Digestive surgery
Research InstitutionFukuta Health University

Principal Investigator

MATSUMOTO Sumio  Fujita Health Univ., Dept of Surgery, Associate Professor, 医学部, 助教授 (80124957)

Co-Investigator(Kenkyū-buntansha) TAN Mitsuaki  Fujita Health Univ., Assistant, 医学部, 助手 (80192186)
TSUKADA Norio  Fujita Health Univ., Assistant, 医学部, 助手 (30201635)
KUTSUNA Tetsuji  Fujita Health Univ., Researcher, 医学部, 研究員 (60175312)
Project Period (FY) 1988 – 1990
KeywordsLymphokine activated killer / Interleukin-2 / Thoracic duct / Major histocompatibility complex / Beta 2 microgobulin / Adopted immunotherapy
Research Abstract

In these several years, we applied LAK induced from thoracic duct lymphocytes to patients with recurrent malignant tumor. Nine patients were treated had LAK induced from thoracic duct lymphocytes and/or peripheral blood lymphocytes. Gastric, breast or pancreatic cancer did not show tumor regress. Three colorectal cancer did not show tumor growth during LAK treatment. One hepatoma case with hepatic, iliac bone and lung metastases showed complete tumor necrosis of hepatic metastasis, however, LAK was ineffective for the iliac bone and lung metastases. Immunohistochemical stain revealed that beta2 microgobulin (BMG) was positive on the cell surface of hepatic metastasis and negative in iliac bone and lung metastatic site. BMG was a small component of major histocompatibility complex class 1 antigen. Our results suggested a possibility that LAK might contain cytotoxic Tlympohcytes or induce them. Until now, we tried to make much more amount or more cytotoxic LAK, but now we investigate again about the antigen presentation on target cell surface and the relation about application and cytotoxic effect of LAK.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] 松本 純夫、他9名: "胸管リンパ球の性格とそれから誘導したLymphokine activated killerの経肝動脈的投与の臨床経験" Oncologia. 22. 92-96 (1989)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 松本 純夫、他14名: "固形癌の進展形成における胸管リンパ液細胞診の意義" Biotherapy. 3. 1181-1184 (1989)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 松本 純夫、他6名: "OKー432経口投与によって誘導される末梢血および胸管リンパ球の細胞障害性の検討ー宿主要因からみた相違ー" 日本消化器外科学会雑誌. 22. 826-830 (1989)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 橋本 誠一,松本 純夫 他6名: "OKー432刺激でリンパ球より得られるkiller細胞の誘導機序" 医学のあゆみ. 153. 647-648 (1990)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Sumio Matsumoto, et al.: "Characterisitics of thoracic duct lympocytes and clinical experiences in adoptive immunotherapy through hepatic artery by lymphokine active killer cells derived from thoracic duct lymphocyte." Oncology. 22(6). 92-96 (1989)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Sumio Matsumoto, et al.: "Significance of cytological survey for thoracic duct lymph in metastatic process of malignant solid tumor." Biotherapy. 3(5). 1181-1184 (1989)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Sumio Matwumoto, et al.: "The effects of oral administration of OK-432 on the cytotoxicities of peripheral and thoracic duct lymphocytes in respect of host factors." J Jap Gastroenterol Surg. 22(3). 826-830 (1989)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Seiji Hashimoto, Sumio Matsumoto, et al.: "Mechanisms of killer cell induction from thoracic duct lymphocytes stimulated with OK-432, a streptococcal preparation." Igaku no Ayumi. 153(11). 647-648 (1990)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1993-08-12  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi